Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Complete title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Research Study Number S1609
 
Principal Investigator Heidi Gray, MD
 
Phase II

Research Study Description

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number S1609
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Head and Neck Cancer; Nasopharyngeal Cancer; Ovarian Cancer; Pituitary Tumor; Salivary Gland Cancer; Solid Tumors; Stomach Cancer; Testicular Cancer; Thyroid Cancer; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumor; Neoplasms; Neoplasms, Glandular and Epithelial; Otorhinolaryngologic Neoplasms; Endocrine Gland Neoplasms; Neoplasms, Squamous Cell; Pharyngeal Neoplasms; Carcinoid Tumor; Immunotherapy; Nerve Sheath Neoplasms; Trophoblastic Neoplasms; Neoplasms, Second Primary; Carotid Body Tumor; Sex Cord-Gonadal Stromal Tumors; Trophoblastic Tumor, Placental Site; Parathyroid Neoplasms; Mixed Tumor, Mullerian; Odontogenic Tumors; Paranasal Sinus Neoplasms

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials